View Older Stories View More Recent Stories

May 7, 2019 04:05PM New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)
May 7, 2019 04:05PM New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)
May 7, 2019 08:43AM Akcea Therapeutics (AKCA), Ionis (IONS) Announce Approval of WAYLIVRA in European Union
May 7, 2019 08:41AM Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union
May 7, 2019 08:41AM Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union
May 6, 2019 07:30AM Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)
May 6, 2019 07:05AM Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
May 2, 2019 07:05AM Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19)
May 2, 2019 07:05AM Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19)
May 1, 2019 07:30AM Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
May 1, 2019 07:05AM Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases
Apr 30, 2019 07:45AM Biogen (BIIB) Reports Data Publication in Neurology Showing that Treatment with SPINRAZA (nusinersen) Improved Motor Function, Provided Long-Term Benefit
Apr 30, 2019 07:33AM Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy
Apr 25, 2019 07:05AM Ionis Pharmaceuticals to hold first quarter 2019 financial results webcast
Apr 24, 2019 07:00AM Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast
Apr 24, 2019 07:00AM Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast
Apr 12, 2019 07:30AM Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference
Apr 8, 2019 04:05PM Ionis Pharmaceuticals to Provide Corporate Update at 2019 Annual Meeting of Stockholders
Mar 25, 2019 07:32AM Ionis Pharmaceuticals (IONS) Announces Brett P. Monia Ph.D. to Board
Mar 25, 2019 07:05AM Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors
Mar 15, 2019 04:06PM Akcea Therapeutics (AKCA), Ionis (IONS) Announce Upcoming Data Presentations at ACC.19
Mar 15, 2019 04:05PM Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
Mar 15, 2019 04:05PM Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
Mar 7, 2019 07:05AM Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Mar 1, 2019 07:48AM Ionis Pharmaceuticals Inc. (IONS), Akcea Therapeutics (AKCA) Report Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
Mar 1, 2019 07:45AM Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
Mar 1, 2019 07:45AM Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
Feb 28, 2019 07:30AM Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy
Feb 28, 2019 07:00AM Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome
Feb 27, 2019 07:00AM Ionis Exceeds 2018 Financial Guidance
Feb 26, 2019 04:05PM Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018
Feb 25, 2019 01:15AM AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License
Feb 25, 2019 01:15AM AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License
Feb 20, 2019 07:00AM Akcea Therapeutics to Present at Upcoming Investor Conferences
Feb 13, 2019 04:05PM Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast
Feb 13, 2019 07:05AM Ionis Pharmaceuticals to Hold 2018 Financial Results Webcast
Jan 28, 2019 07:07AM Ionis Pharmaceuticals (IONS) Reports First Patient Enrollment in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
Jan 28, 2019 07:00AM First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
Jan 2, 2019 07:05AM Ionis Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
Dec 20, 2018 05:41PM Ionis Announces Plans for Management Transitions in 2020
Dec 6, 2018 07:33AM Biogen (BIIB) Exercises Option with Ionis (IONS) to Develop, Commercialize Investigational Treatment BIIB067 for Subtype of Familial ALS Based on Positive Phase 1 Data
Dec 6, 2018 07:30AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
Dec 6, 2018 07:30AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
Nov 29, 2018 07:30AM International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
Nov 29, 2018 07:30AM International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
Nov 27, 2018 07:00AM First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting
Nov 13, 2018 07:07AM Ionis Pharmaceuticals to Present at Jefferies 2018 London Healthcare Conference
Nov 12, 2018 06:58AM Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Highlight Phase 2 Results on AKCEA-APO(a)-LRx in Late-Breaking Clinical Trial Presentation
Nov 12, 2018 06:55AM Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
Nov 12, 2018 06:55AM Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
View More Recent Stories View Older Stories